Mir145 (microRNA 145) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Mir145 (microRNA 145) Rattus norvegicus
Analyze
Symbol: Mir145
Name: microRNA 145
RGD ID: 2325565
Description: Predicted to enable mRNA 3'-UTR binding activity and mRNA base-pairing translational repressor activity. Involved in several processes, including positive regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching; response to ischemia; and retina layer formation. Predicted to be located in extracellular exosome. Predicted to be part of RISC complex. Used to study glaucoma and myocardial infarction. Biomarker of biliary atresia; congestive heart failure; diabetes mellitus; liver disease (multiple); and pulmonary hypertension. Orthologous to human MIR145 (microRNA 145); INTERACTS WITH aflatoxin B1; atrazine; bleomycin A2.
Type: ncrna (Ensembl: miRNA)
RefSeq Status: PROVISIONAL
Previously known as: microRNA mir-145; rno-mir-145
RGD Orthologs
Human
Mouse
Dog
Pig
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81857,369,983 - 57,370,070 (-)NCBIGRCr8
mRatBN7.21855,099,640 - 55,099,727 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1855,099,640 - 55,099,727 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1857,193,356 - 57,193,443 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01857,907,967 - 57,908,054 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01855,723,506 - 55,723,593 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01856,969,907 - 56,969,994 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1856,969,907 - 56,969,994 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01856,198,820 - 56,198,907 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1853,250,138 - 53,250,225 (-)NCBICelera
Cytogenetic Map18q12.1NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
aorta smooth muscle tissue morphogenesis  (ISO)
cardiac vascular smooth muscle cell differentiation  (ISO)
cellular response to amino acid stimulus  (ISO)
cellular response to estrogen stimulus  (ISO)
cellular response to ethanol  (ISO)
cellular response to hydroperoxide  (IEP)
cellular response to leukemia inhibitory factor  (ISO)
ectodermal cell differentiation  (ISO)
hematopoietic stem cell proliferation  (ISO)
long-term synaptic potentiation  (ISO)
mesodermal cell differentiation  (ISO)
miRNA-mediated gene silencing by inhibition of translation  (ISO)
miRNA-mediated gene silencing by mRNA destabilization  (ISO)
miRNA-mediated post-transcriptional gene silencing  (ISO)
negative regulation of angiogenesis  (ISO)
negative regulation of cardiac muscle cell apoptotic process  (ISO)
negative regulation of cell migration  (ISO)
negative regulation of cellular response to transforming growth factor beta stimulus  (ISO)
negative regulation of cholesterol efflux  (ISO)
negative regulation of epithelial to mesenchymal transition  (ISO)
negative regulation of extracellular matrix assembly  (ISO)
negative regulation of inflammatory response  (ISO)
negative regulation of interleukin-16 production  (ISO)
negative regulation of SMAD protein signal transduction  (ISO)
negative regulation of somatic stem cell division  (ISO)
negative regulation of somatic stem cell population maintenance  (ISO)
negative regulation of transforming growth factor beta receptor signaling pathway  (ISO)
positive regulation of cellular response to hypoxia  (ISO)
positive regulation of interleukin-10 production  (ISO)
positive regulation of macrophage activation  (ISO)
positive regulation of macrophage differentiation  (ISO)
positive regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching  (IMP)
response to alkaloid  (IEP)
response to ischemia  (IEP)
retina layer formation  (IMP)
transforming growth factor beta receptor signaling pathway  (ISO)

Cellular Component

Molecular Function

References

References - curated
# Reference Title Reference Citation
1. MiR-145 facilitates proliferation and migration of endothelial progenitor cells and recanalization of arterial thrombosis in cerebral infarction mice via JNK signal pathway. Chen R, etal., Int J Clin Exp Pathol. 2015 Oct 1;8(10):13770-6. eCollection 2015.
2. Long noncoding RNA myocardial infarction associated transcript promotes the development of thoracic aortic by targeting microRNA-145 via the PI3K/Akt signaling pathway. Chen S, etal., J Cell Biochem. 2019 Sep;120(9):14405-14413. doi: 10.1002/jcb.28695. Epub 2019 Apr 15.
3. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Cheng Y, etal., Circ Res. 2009 Jul 17;105(2):158-66. doi: 10.1161/CIRCRESAHA.109.197517. Epub 2009 Jun 18.
4. miR-145 attenuates cardiac fibrosis through the AKT/GSK-3β/β-catenin signaling pathway by directly targeting SOX9 in fibroblasts. Cui S, etal., J Cell Biochem. 2021 Feb;122(2):209-221. doi: 10.1002/jcb.29843. Epub 2020 Sep 5.
5. Circulatory microRNA-145 expression is increased in cerebral ischemia. Gan CS, etal., Genet Mol Res. 2012 Jan 27;11(1):147-52. doi: 10.4238/2012.January.27.1.
6. Plasma Levels of microRNA-145 Are Associated with Severity of Coronary Artery Disease. Gao H, etal., PLoS One. 2015 May 4;10(5):e0123477. doi: 10.1371/journal.pone.0123477. eCollection 2015.
7. Long noncoding RNA MALAT1 mediates cardiac fibrosis in experimental postinfarct myocardium mice model. Huang S, etal., J Cell Physiol. 2019 Mar;234(3):2997-3006. doi: 10.1002/jcp.27117. Epub 2018 Aug 26.
8. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Ikemura K, etal., Mol Pharmacol. 2013 Feb;83(2):399-405. doi: 10.1124/mol.112.081844. Epub 2012 Nov 19.
9. Circular RNA Sirtuin1 represses pulmonary artery smooth muscle cell proliferation, migration and autophagy to ameliorate pulmonary hypertension via targeting microRNA-145-5p/protein kinase-B3 axis. Jing X, etal., Bioengineered. 2022 Apr;13(4):8759-8771. doi: 10.1080/21655979.2022.2036302.
10. Associations Between miRNAs and Two Different Cancers: Breast and Colon. Kundaktepe BP, etal., Cancer Manag Res. 2020 Feb 7;12:871-879. doi: 10.2147/CMAR.S227628. eCollection 2020.
11. P38 MAPK Signaling Pathway Mediates Angiotensin II-Induced miR143/145 Gene Cluster Downregulation during Aortic Dissection Formation. Li B, etal., Ann Vasc Surg. 2017 Apr;40:262-273. doi: 10.1016/j.avsg.2016.09.016. Epub 2017 Feb 4.
12. Investigation of the clinical significance and prognostic value of microRNA-145 in human hepatocellular carcinoma. Li P, etal., Medicine (Baltimore). 2018 Dec;97(51):e13715. doi: 10.1097/MD.0000000000013715.
13. MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H(2)O(2))-induced apoptosis through targeting the mitochondria apoptotic pathway. Li R, etal., PLoS One. 2012;7(9):e44907. doi: 10.1371/journal.pone.0044907. Epub 2012 Sep 18.
14. Regulatory Mechanism of MicroRNA-145 in the Pathogenesis of Acute Aortic Dissection. Li T, etal., Yonsei Med J. 2019 Apr;60(4):352-359. doi: 10.3349/ymj.2019.60.4.352.
15. Effects of flavonoids on MicroRNA 145 regulation through Klf4 and myocardin in neointimal formation in vitro and in vivo. Lin CM, etal., J Nutr Biochem. 2018 Feb;52:27-35. doi: 10.1016/j.jnutbio.2017.08.016. Epub 2017 Sep 14.
16. Correlation between miR-21 and miR-145 and the incidence and prognosis of colorectal cancer. Liu Q, etal., J BUON. 2018 Jan-Feb;23(1):29-35.
17. Over-expression of microRNA-145 drives alterations in β-adrenergic signaling and attenuates cardiac remodeling in heart failure post myocardial infarction. Liu Z, etal., Aging (Albany NY). 2020 Jun 18;12(12):11603-11622. doi: 10.18632/aging.103320. Epub 2020 Jun 18.
18. MicroRNA-145 Protects against Myocardial Ischemia Reperfusion Injury via CaMKII-Mediated Antiapoptotic and Anti-Inflammatory Pathways. Liu Z, etal., Oxid Med Cell Longev. 2019 Sep 10;2019:8948657. doi: 10.1155/2019/8948657. eCollection 2019.
19. Overexpression of MicroRNA-145 Promotes Ascending Aortic Aneurysm Media Remodeling through TGF-β1. Pei H, etal., Eur J Vasc Endovasc Surg. 2015 Jan;49(1):52-9. doi: 10.1016/j.ejvs.2014.10.018.
20. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
21. Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients. Santovito D, etal., Expert Opin Ther Targets. 2013 Mar;17(3):217-23. doi: 10.1517/14728222.2013.745512. Epub 2013 Jan 23.
22. miR-145-5p attenuates inflammatory response and apoptosis in myocardial ischemia-reperfusion injury by inhibiting (NADPH) oxidase homolog 1. Tan L, etal., Exp Anim. 2021 Aug 6;70(3):311-321. doi: 10.1538/expanim.20-0160. Epub 2021 Mar 4.
23. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Wang CJ, etal., Dis Markers. 2009;26(1):27-34. doi: 10.3233/DMA-2009-0601.
24. Long noncoding RNA H19 suppresses cardiac hypertrophy through the MicroRNA-145-3p/SMAD4 axis. Wang H, etal., Bioengineered. 2022 Feb;13(2):3826-3839. doi: 10.1080/21655979.2021.2017564.
25. LncRNA TUG1 Promotes Apoptosis, Invasion, and Angiogenesis of Retinal Endothelial Cells in Retinopathy of Prematurity via MiR-145-5p. Wang Y, etal., Front Med (Lausanne). 2022 Apr 4;9:803214. doi: 10.3389/fmed.2022.803214. eCollection 2022.
26. MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome. Wu S, etal., Eur J Med Res. 2020 Mar 17;25(1):2. doi: 10.1186/s40001-020-00403-8.
27. The miR-143/145 cluster reverses the regulation effect of KLF5 in smooth muscle cells with proliferation and contractility in intracranial aneurysm. Xu J, etal., Gene. 2018 Dec 30;679:266-273. doi: 10.1016/j.gene.2018.09.010. Epub 2018 Sep 7.
28. MicroRNA-145-5p targeting of TRIM2 mediates the apoptosis of retinal ganglion cells via the PI3K/AKT signaling pathway in glaucoma. Xu K, etal., J Gene Med. 2021 Nov;23(11):e3378. doi: 10.1002/jgm.3378. Epub 2021 Aug 10.
29. Downregulation of microRNA-145 may contribute to liver fibrosis in biliary atresia by targeting ADD3. Ye Y, etal., PLoS One. 2017 Sep 13;12(9):e0180896. doi: 10.1371/journal.pone.0180896. eCollection 2017.
30. Downregulation of miR143/145 gene cluster expression promotes the aortic media degeneration process via the TGF-β1 signaling pathway. Zhang M and Wang Z, Am J Transl Res. 2019 Jan 15;11(1):370-378. eCollection 2019.
31. Circulating MicroRNA-145 is Associated with Acute Myocardial Infarction and Heart Failure. Zhang M, etal., Chin Med J (Engl). 2017 5th Jan 2017;130(1):51-56. doi: 10.4103/0366-6999.196573.
32. Hypermethylation of the Micro-RNA 145 Promoter Is the Key Regulator for NLRP3 Inflammasome-Induced Activation and Plaque Formation. Zhong W, etal., JACC Basic Transl Sci. 2018 Sep 19;3(5):604-624. doi: 10.1016/j.jacbts.2018.06.004. eCollection 2018 Oct.
33. MicroRNA-145 inhibits hepatic stellate cell activation and proliferation by targeting ZEB2 through Wnt/β-catenin pathway. Zhou DD, etal., Mol Immunol. 2016 Jul;75:151-60. doi: 10.1016/j.molimm.2016.05.018. Epub 2016 Jun 9.
Additional References at PubMed
PMID:15345052   PMID:16381832   PMID:16766679   PMID:17604727   PMID:18791161   PMID:19091803   PMID:19816508   PMID:20403161   PMID:20439489   PMID:20548288   PMID:21276775   PMID:21690067  
PMID:21762377   PMID:23185045   PMID:23702479   PMID:24043548   PMID:24106971   PMID:24166492   PMID:25139829   PMID:25858512   PMID:26119485   PMID:26432843   PMID:27459539   PMID:27907012  
PMID:28980287   PMID:29030988   PMID:29057271   PMID:29072705   PMID:29178342   PMID:29217135   PMID:29758198   PMID:29925839   PMID:29956747   PMID:30179678   PMID:30465949   PMID:30729278  
PMID:30747413   PMID:31070083   PMID:31425342   PMID:33185386   PMID:33378041   PMID:33945431   PMID:33984358   PMID:34036377   PMID:34122720   PMID:34767671   PMID:35082354   PMID:35579106  
PMID:35809317   PMID:36722155   PMID:37329866   PMID:38158661  


Genomics

Comparative Map Data
Mir145
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81857,369,983 - 57,370,070 (-)NCBIGRCr8
mRatBN7.21855,099,640 - 55,099,727 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1855,099,640 - 55,099,727 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1857,193,356 - 57,193,443 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01857,907,967 - 57,908,054 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01855,723,506 - 55,723,593 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01856,969,907 - 56,969,994 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1856,969,907 - 56,969,994 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01856,198,820 - 56,198,907 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1853,250,138 - 53,250,225 (-)NCBICelera
Cytogenetic Map18q12.1NCBI
MIR145
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh385149,430,646 - 149,430,733 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl5149,430,646 - 149,430,733 (+)EnsemblGRCh38hg38GRCh38
GRCh375148,810,209 - 148,810,296 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 365148,790,401 - 148,790,488 (+)NCBINCBI36Build 36hg18NCBI36
Celera5144,892,189 - 144,892,276 (+)NCBICelera
Cytogenetic Map5q32NCBI
HuRef5143,956,545 - 143,956,632 (+)NCBIHuRef
CHM1_15148,242,644 - 148,242,731 (+)NCBICHM1_1
T2T-CHM13v2.05149,965,492 - 149,965,579 (+)NCBIT2T-CHM13v2.0
Mir145a
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391861,780,896 - 61,780,965 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1861,780,896 - 61,780,965 (-)EnsemblGRCm39 Ensembl
GRCm381861,647,825 - 61,647,894 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1861,647,825 - 61,647,894 (-)EnsemblGRCm38mm10GRCm38
MGSCv371861,807,479 - 61,807,548 (-)NCBIGRCm37MGSCv37mm9NCBIm37
Celera1862,930,620 - 62,930,689 (-)NCBICelera
Cytogenetic Map18E1NCBI
cM Map1834.64NCBI
MIR145
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1459,533,128 - 59,533,210 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl459,533,128 - 59,533,210 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha459,298,427 - 59,298,509 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0460,015,687 - 60,015,769 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl460,015,687 - 60,015,769 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1459,802,584 - 59,802,666 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0459,917,043 - 59,917,125 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0460,447,590 - 60,447,672 (-)NCBIUU_Cfam_GSD_1.0
MIR145
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl2150,580,126 - 150,580,211 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.12150,580,126 - 150,580,211 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.22157,346,127 - 157,346,212 (+)NCBISscrofa10.2Sscrofa10.2susScr3

miRNA Target Status

Confirmed Targets
Gene TargetMature miRNAMethod NameResult TypeData TypeSupport TypePMID
Sod2rno-miR-145-5pMirtarbaseexternal_infoqRT-PCR//Western blot//MicroarrayFunctional MTI19142192
Klf5rno-miR-145-5pMirtarbaseexternal_infoLuciferase reporter assay//qRT-PCR//Western blot//Functional MTI19542014
Bnip3rno-miR-145-5pMirtarbaseexternal_infoLuciferase reporter assay//Western blotFunctional MTI23028672
Myocdrno-miR-145-5pMirtarbaseexternal_infoqRT-PCRFunctional MTI (Weak)19542014

Predicted Targets
Summary Value
Count of predictions:9286
Count of gene targets:5816
Count of transcripts:6254
Interacting mature miRNAs:rno-miR-145-3p, rno-miR-145-5p
Prediction methods:Microtar, Miranda, Pita, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
2299160Iddm35Insulin dependent diabetes mellitus QTL 352.79blood glucose amount (VT:0000188)age at onset/diagnosis of type 1 diabetes mellitus (CMO:0001140)18420794160377792Rat
2293708Bss46Bone structure and strength QTL 468.80.0001lumbar vertebra morphology trait (VT:0010494)lumbar vertebra cortical cross-sectional area (CMO:0001690)181179151863636873Rat
1578661Bss20Bone structure and strength QTL 203.7femur morphology trait (VT:0000559)femoral neck cross-sectional area (CMO:0001697)181179151883218561Rat
1578667Bss21Bone structure and strength QTL 213.5femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)181179151883218561Rat
1358358Sradr6Stress Responsive Adrenal Weight QTL 62.49adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)181194429959330563Rat
6903359Bp355Blood pressure QTL 3553.6arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)181194454459796478Rat
2313082Bss85Bone structure and strength QTL 850.80.0001long bone metaphysis morphology trait (VT:0000133)tibia midshaft total cross-sectional area (CMO:0001715)181495133759951337Rat
1358193Emca2Estrogen-induced mammary cancer QTL 21.6mammary gland integrity trait (VT:0010552)post-insult time to mammary tumor formation (CMO:0000345)181800759963571040Rat
1600373Mamtr6Mammary tumor resistance QTL 6mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)181927890183218561Rat
1331741Bp232Blood pressure QTL 2323.59112arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)182137289383213037Rat
1331733Bp233Blood pressure QTL 2333.97196arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182479697779788953Rat
2325839Bp348Blood pressure QTL 3480.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182557098570570985Rat
2293704Bss35Bone structure and strength QTL 354.590.0002femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)182896485373964853Rat
2300157Bmd66Bone mineral density QTL 6613.10.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)182896485373964853Rat
2300177Bmd65Bone mineral density QTL 6519.70.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)182896485373964853Rat
9589816Gluco68Glucose level QTL 687.250.001blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)182979296574792965Rat
8694378Bw157Body weight QTL 1573.590.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)182979296574792965Rat
9590318Scort22Serum corticosterone level QTL 227.640.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)182979296574792965Rat
1331754Bp230Blood pressure QTL 2304.61609arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)182979296574792965Rat
738005Anxrr11Anxiety related response QTL 113.4exploratory behavior trait (VT:0010471)number of entries into a discrete space in an experimental apparatus (CMO:0000960)183003981375039813Rat
61383Bp47Blood pressure QTL 4717.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)183127168160377755Rat
1331742Bp228Blood pressure QTL 2283.88752arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
1331774Bp226Blood pressure QTL 2264.41065arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
1331776Bp225Blood pressure QTL 2252.829arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)183135940859796643Rat
1331798Bp224Blood pressure QTL 2243.53873arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940859796643Rat
1331727Bp237Blood pressure QTL 2373.053arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135940861698465Rat
61429Cia17Collagen induced arthritis QTL 174.6joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)183135940870263868Rat
2303120Mamtr8Mammary tumor resistance QTL 80.001mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)183135940883218561Rat
6903347Bp350Blood pressure QTL 3504.4arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)183135953059796478Rat
631274Sprol1Serum protein level QTL 15.3blood total protein amount (VT:0005567)serum total protein level (CMO:0000661)183139332077209694Rat
631518Bw11Body weight QTL 112.8body mass (VT:0001259)body weight (CMO:0000012)183587072380870723Rat
61367Iddm4Insulin dependent diabetes mellitus QTL 42.330.0074blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)183819245583192455Rat
1598826Anxrr20Anxiety related response QTL 203.04body movement coordination trait (VT:0005424)number of rearing movements in an experimental apparatus (CMO:0001752)184143297183828827Rat
6893683Bw110Body weight QTL 1102.70.002body mass (VT:0001259)body weight (CMO:0000012)184334502283828827Rat
8694366Abfw8Abdominal fat weight QTL 86.380.001visceral adipose mass (VT:0010063)abdominal fat pad weight to body weight ratio (CMO:0000095)184664067583828827Rat
8694432Bw165Body weight QTL 1653.810.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)184664067583828827Rat
9589041Epfw12Epididymal fat weight QTL 1217.080.001epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)184664067583828827Rat
1331806Bp229Blood pressure QTL 2294.36484arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671876357867167Rat
1331736Bp227Blood pressure QTL 2272.791arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)184671876359796643Rat
1331780Bp238Blood pressure QTL 2383.269arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671876359796643Rat
6903345Bp349Blood pressure QTL 3493.9arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
6903349Bp351Blood pressure QTL 3513.5arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
6903351Bp352Blood pressure QTL 3523.3arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)184671893559796478Rat
61360EaeyExperimental allergic encephalomyelitis QTL y3nervous system integrity trait (VT:0010566)experimental autoimmune encephalomyelitis duration (CMO:0001424)184698893960377753Rat
2303571Bw92Body weight QTL 923body mass (VT:0001259)body weight (CMO:0000012)184852004483828827Rat
2303584Gluco55Glucose level QTL 552blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)184852004483828827Rat
7411719Strs5Sensitivity to stroke QTL 59.4cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)184999995865845095Rat
2293658Bmd23Bone mineral density QTL 237.30.0001femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)185146473363636873Rat
738008Hcar14Hepatocarcinoma resistance QTL 144.3liver integrity trait (VT:0010547)liver nonremodeling tumorous lesion number (CMO:0001462)185146473383218561Rat
1331730Scl27Serum cholesterol level QTL 273.826blood HDL cholesterol amount (VT:0000184)serum high density lipoprotein cholesterol level (CMO:0000361)185229287559796643Rat
1331752Bw27Body weight QTL 272.963body mass (VT:0001259)body weight (CMO:0000012)185229287565845095Rat
1359020Ppulsi2Prepulse inhibition QTL 22.71prepulse inhibition trait (VT:0003088)acoustic startle response measurement (CMO:0001519)185229287573997283Rat
1600375Mcs22Mammary carcinoma susceptibility QTL 223.3mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)185253976363933058Rat
631509Sald2Serum aldosterone level QTL 22.9blood aldosterone amount (VT:0005346)serum aldosterone level (CMO:0000487)185253976369140759Rat
12880368Bw187Body weight QTL 1870.045body mass (VT:0001259)body weight (CMO:0000012)185253976376104388Rat
12904067Cm122Cardiac mass QTL 1220.001heart mass (VT:0007028)heart wet weight to body weight ratio (CMO:0002408)185253976376104388Rat
12904069Cm123Cardiac mass QTL 1230.001heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)185253976376104388Rat
12904070Cm124Cardiac mass QTL 1240.01heart right ventricle mass (VT:0007033)heart right ventricle weight to body weight ratio (CMO:0000914)185253976376104388Rat
12904071Am18Aortic mass QTL 180.001aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)185253976376104388Rat
12904073Kidm71Kidney mass QTL 710.001kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)185253976376104388Rat
2301417Bp319Blood pressure QTL 3190.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)185253976376104388Rat
1300125Rf26Renal function QTL 263.2urine potassium amount (VT:0010539)urine potassium excretion rate (CMO:0000761)185253986365844950Rat
1298072Cia26Collagen induced arthritis QTL 263.6joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)185470976983828827Rat


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 7 1 2 1 1 4 13 10 1
Low 36 30 15 17 15 7 9 43 26 23 1 7
Below cutoff 4 4 4 8 1

Sequence

Nucleotide Sequences
RefSeq Transcripts NR_031891 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
GenBank Nucleotide JAXUCZ010000018 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles

RefSeq Acc Id: ENSRNOT00000053597
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1855,099,640 - 55,099,727 (-)Ensembl
Rnor_6.0 Ensembl1856,969,907 - 56,969,994 (-)Ensembl
RefSeq Acc Id: NR_031891
RefSeq Status: PROVISIONAL
Type: NON-CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81857,369,983 - 57,370,070 (-)NCBI
mRatBN7.21855,099,640 - 55,099,727 (-)NCBI
Rnor_6.01856,969,907 - 56,969,994 (-)NCBI
Rnor_5.01856,198,820 - 56,198,907 (-)NCBI
Celera1853,250,138 - 53,250,225 (-)NCBI
Sequence:
Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2325565 AgrOrtholog
BioCyc Gene G2FUF-7310 BioCyc
Ensembl Genes ENSRNOG00000035474 Ensembl, ENTREZGENE
Ensembl Transcript ENSRNOT00000053597 ENTREZGENE
miRBase MI0000918 ENTREZGENE
NCBI Gene 100314036 ENTREZGENE
PhenoGen Mir145 PhenoGen
RatGTEx ENSRNOG00000035474 RatGTEx
RNAcentral URS0000527F89 RNACentral
  URS000075B7E1 RNACentral
  URS000075C5A7 RNACentral


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2013-08-14 Mir145  microRNA 145  Mir145  microRNA mir-145  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2010-06-02 Mir145  microRNA mir-145      Symbol and Name status set to provisional 70820 PROVISIONAL